Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Methotrexate with corticosteroids can help regrow hair in severe alopecia areata but may cause relapses and side effects.

Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.

Follicular unit extraction successfully restored hair growth in a leprosy patient without disease relapse.

A 5-year-old boy with alopecia totalis had temporary hair regrowth with treatment but relapsed, highlighting the need for thorough investigation and holistic care.

Combining nonablative fractional laser with minoxidil was effective for alopecia areata with only one patient relapsing after a year.

A dog with complete hair loss regrew most hair after treatment, with no relapse after stopping treatment.

There are no FDA-approved treatments for Alopecia Areata, and current options have varying success and relapse rates.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Pulse steroid therapy for alopecia areata shows a 43% complete response rate but has a high relapse rate, especially in children.

Diphenylcyclopropenone (DPCP) can help regrow hair in many alopecia areata patients but may cause side effects and relapses.

DPCP is effective for treating severe alopecia areata, but relapse is common.

Alopecia areata severity is influenced by factors like long disease duration, relapses, treatment response, and mental health, leading to the creation of a new severity measurement tool.

Platelet-rich plasma is a safe and effective treatment for hair loss, with fewer relapses than steroid treatment.

Platelet-Rich Plasma treatment has limited and temporary effects on severe Alopecia Areata and does not prevent relapses.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Corticosteroids may not effectively control oxidative stress in alopecia areata, possibly leading to relapses.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.

Alopecia areata's causes are unclear, treatments exist but relapses are common.

Alopecia areata was most common in people in their 30s and 40s, with some family history and a higher relapse rate, and larger bald areas responded better to specific immunotherapy.

Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.

Herbal lotions are effective for severe hair loss, with a 64.8% success rate, but relapse is common and long-term management requires allergen control and possible corticosteroid use.

Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.

Younger patients and those with more hair loss are less likely to benefit from oral steroid treatment for hair loss, and low vitamin D may predict relapse.

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.

No effective treatment for frontal fibrosing alopecia was found, but oral 5-alpha-reductase inhibitors had the best response; for lichen planopilaris, topical corticosteroids were commonly used but had a high relapse rate.

Chinese patients with primary cicatricial alopecia often have folliculitis decalvans, benefit from treatment, but may experience relapse, with dermoscopy being a useful diagnostic tool.

Contact immunotherapy can improve hair regrowth in alopecia areata patients.

Hair loss can occur as a side effect of certain breast cancer treatments, but minoxidil can help regrow hair.